Question 1: computed tomography (CT) images show multiple, expansile osteolytic lesions involving the mandible and maxilla, with variability in size. The largest involved the body of the left mandible and measured 3.7 × 37.7 × 31.9 cm , with cortical expansion, erosions, and multiple loculations. No peri-osteal reaction and no definite associated soft-tissue masses. Question 2: brown tumor of the mandible due to secondary hyperparathyroidism (SHPT). Question 3: the management of the brown tumor depends on the severity of the lesion. Control of hyperparathyroidism is critical, as normalization of parathyroid hormone (PTH) levels typically leads to the regression of the tumor size or even resolution. Surgical resection may be indicated for large, disfiguring tumors that fail to regress with medical treatment. Parathyroidectomy and renal transplantation could resolve the tumor.
Discussion
We present a case of Brown tumor in young child originating from the craniofacial bones associated with refractory SHPT. Chronic kidney disease (CKD) is associated with a disturbance of mineral and bone homeostasis. This condition is termed CKD-mineral bone disorder (CKD-MBD) and represents an obstacle to optimal bone strength, final adult height, and cardiovascular health [1] . Impaired renal function with progressive glomerular filtration rate (GFR) reduction stimulates a number of compensatory mechanisms, including the increase in bone fibroblast growth factor-23 (FGF-23). FGF23 binds to its receptor FGFR1 and co-receptor Klotho in the kidney, a key consequence in CKD being reduced 1-hydroxylase activity, resulting in decreased circulating 1,25 (OH)2 D with consequent SHPT [2] . High-turnover renal osteodystrophy and osteitis fibrosa cystica are the consequences of these changes [3] .
Chronic hyperparathyroidism increases bone remodeling, leading to rapid osteoclastic activity, erosive bony lesions and peritrabecular fibrosis, which can result in a local destructive phenomenon called brown tumor [4] . Bone pain and fractures are common complications [5, 6] . Brown tumors can be located in any part of the skeleton, but are most frequently encountered in the ribs, clavicles, extremities, and pelvic girdle. Clinically significant lesions in the craniofacial bones are rare [7] [8] [9] . Costal lesions are more frequent than spinal lesions [6] . Brown tumors can also be multifocal [6] and have also been reported in children on prolonged hemodialysis [10, 11] . A brief review of published pediatric cases is summarized in Table 1 .
The diagnosis of brown tumor is established through medical history, clinical examination, laboratory findings, and radiological imaging.
Borzych et al. reported that at least 1 in 6 children on chronic dialysis show radiological and/or clinical signs of bone disease and 44 % develop severe secondary HPT with PTH levels five times above the upper limit of normal, with a 10 % higher likelihood of developing severe HPT for each year on dialysis [14] .
This fits with our patient, who had been on long-term dialysis for 7 years, increasing the risk of complications associated with end-stage kidney disease (ESKD), including CKD-MBD and brown tumor. Our patient had persistent hyperphosphatemia and poor metabolic control despite his regular hemodialysis. Compliance with medications was thought to be inconsistent. Potentially, more frequent and/or prolonged dialysis would have prevented or ameliorated the complications. Cinacalcet was added to his medications at 10 years of age, with no significant response, again potentially reflecting the poor compliance or refractory SHPT. Cinacalcet is a calcimimetic that down-regulates PTH levels and subsequently serum calcium and phosphate levels in patients with SHPT on dialysis [15] . Treatment with cinacalcet for 9 months showed evidence of revision of high bone turnover bone disease toward normal in the majority of patients, based on histomorphometry [2] . However, its use in children is not approved by the Food and Drug Administration (FDA). Pediatric clinical trials are on hold following the death of a 14-year-old patient in February 2013 [16] .
Parathyroidectomy (PTX) is another potential treatment option in severe renal HPT that is refractory to medical treatment. HPT is a potential complication after extended PTX. Supplementation with calcium and activated vitamin D is needed in these patients to prevent hypocalcemia with all its clinical manifestations, such as seizures, tetany, and arrhythmia. Symptomatic hypocalcemia is most likely to occur in patients with poor compliance with medications. PTX needs to be carefully considered in each individual patient. The timing and extent of parathyroidectomy require an interdisciplinary approach from both nephrologist and endocrine surgeons [17] .
One potentially overlooked contributor to CKD-MBD is metabolic acidosis, as it results in bone demineralization and release of sodium, potassium, and calcium. Furthermore, metabolic acidosis stimulates osteoclasts and suppresses osteoblast activity, leading to direct dissolution of bone [18] .
Graham et al. concluded that the correction of metabolic acidosis increases the sensitivity of the parathyroid gland to the ionized calcium, leading to its suppression [19] .
Normalizing PTH level with medications, dialysis, parathyroidectomy, or kidney transplantation often leads to tumor regression or resolution [4] . Surgical resection of a brown tumor should only be considered if the patient needs quick resolution when body functions are being compromised or there is facial deformation [20] .
The management of CKD-MBD remains a challenge in children with ESKD. Our case demonstrates the importance of meticulous attention to markers of CKD-MBD, their correction with medications and/or intensified dialysis, and, ideally, early renal transplantation to prevent such serious complications. 
